经导管三尖瓣置换术治疗左心瓣膜术后重度三尖瓣反流的临床疗效分析  

Clinical efficacy of transcatheter tricuspid valve replacement for isolated severe tricuspid regurgitation after left-side valve surgery

作　　者：谭桐 付冰奇 马坚锐 刘浩忠 刘健[1,3] 黄焕雷 陈寄梅[1,3] 庄建 郭惠明[1,3] TAN Tong;FU Bingqi;MA Jianrui;LIU Haozhong;LIU Jian;HUANG Huanlei;CHEN Jimei;ZHUANG Jian;GUO Huiming(Guangdong Cardiovascular Institute,Guangdong Provincial People′s Hospital,Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou,510080,China;Beijing Anzhen Hospital,Capital Medical University;Guangdong Provincial Key Laboratory of South China Structural Heart Disease;Fuwai Hospital,National Center for Cardiovascular Disease,Chinese Academy of Medical Sciences and Peking Union Medical College)

机构地区：[1]广东省心血管病研究所、南方医科大学附属广东省人民医院(广东省医学科学院),广州510080 [2]首都医科大学附属北京安贞医院 [3]广东省华南结构性心脏病重点实验室 [4]中国医学科学院北京协和医学院、国家心血管病中心、阜外医院

出　　处：《临床心血管病杂志》2024年第1期52-56,共5页Journal of Clinical Cardiology

基　　金：广州市科技计划基金(No:202002030039);广州市科技计划项目(No:202201010768);广东省基础与应用基础研究基金(No:2022A1515010157);广州地区临床高新、重大和特色技术项目(No:2023P-ZD09);广东省心血管系统疾病临床医学研究中心项目(No:2020B1111170011);广东省人民医院心血管专项(No:2020XXG010)。

摘　　要：目的:评估经导管三尖瓣置换术治疗左心瓣膜术后重度三尖瓣反流的临床疗效。方法:2020年10月—2022年10月,共7例左心瓣膜术后重度三尖瓣反流患者于广东省人民医院(广东省心血管病研究所)接受经导管三尖瓣置换术治疗,其中5例采用Lux-Valve装置(经右心房径路),2例采用Lux-Valve Plus装置(经颈静脉径路)。收集患者住院诊疗及随访资料,总结和分析临床效果。结果:患者年龄为(65.1±8.8)岁,以女性居多(5/7),5例(71.4%)患者伴随下肢水肿等典型右心衰竭症状;患者术前三尖瓣反流均达4+及以上,CRS评分中值8.0分,Child-Pugh评分均值7.3分,肺动脉收缩压(38.9±10.1)mmHg(1 mmHg=0.133 kPa),右室面积变化分数(42.3±3.6)%,三尖瓣环收缩期位移(15.6±1.8)mm。术中顺利置入经导管三尖瓣装置,术后即刻器械成功率、手术成功率达100%(即刻三尖瓣反流改善至1+瓣周漏2例,5例无反流),无死亡、中转开胸、瓣膜移位等并发症。平均随访(14.2±10.2)个月,期间所有患者的人工三尖瓣瓣膜装置功能良好,仅1例患者残余1+的瓣周漏,与术前比较仍显著改善(P<0.001),无中度以上肺动脉高压、肝静脉逆流、再次手术或因心力衰竭住院;NYHA心功能等级均恢复至Ⅱ级。结论:在右心衰竭早期对左心瓣膜术后重度三尖瓣反流患者行经导管三尖瓣置换术是安全可靠的,早中期临床结果优异,重度三尖瓣反流得到显著改善。未来仍需更进一步研究明确经导管三尖瓣置换系统对此类患者的疗效和优势。Objective To evaluate the clinical efficacy of transcatheter tricuspid valve replacement(TTVR)for isolated severe tricuspid regurgitation following left-side valve surgery.Methods From October 2020 to October 2022,seven patients with isolated severe tricuspid regurgitation after left-side valve surgery underwent TTVR at Guangdong Provincial People's Hospital(Guangdong Institute of Cardiovascular Diseases).Among them,five were treated with the Lux-Valve device(via the right atrial pathway),and two with the Lux-Valve Plus device(via the jugular vein pathway).Inpatient treatment and follow-up data were collected for summarizing and analyzing clinical outcomes.Results The mean age of the patients was(65.1±8.8)years,with a female predominance(5/7).Five patients(71.4%)exhibited typical right heart failure symptoms such as lower limb edema.All patients had preoperative tricuspid regurgitation of 4+or greater,a median CRS score of 8.0,average Child-Pugh score of 7.3,pulmonary artery systolic pressure of(38.9±10.1)mmHg,fractional area change of right ventricular(42.3±3.6)%,tricuspid annular plane systolic excursion 15.6±1.8 mm.Intraoperatively,the transcatheter tricuspid valve device was successfully placed,with an immediate postoperative device success rate and surgical success rate of 100%(immediate tricuspid regurgitation improvement,2 cases of 1+perivalvular leakage,5 cases with no regurgitation).No complications such as death,thoracotomy conversion,or valve displacement occurred.The mean follow-up time was(14.2±10.2)months,during which the prosthetic tricuspid valve devices all functioned well.Only one patient had residual 1+perivalvular leakage,significantly improved compared to preoperative conditions(P<0.001).There were no instances of more than moderate pulmonary hypertension,hepatic venous regurgitation,reoperation,or hospitalization for heart failure.All NYHA cardiac function classes recovered to ClassⅡ.Conclusion Transcatheter tricuspid valve replacement is safe and reliable in patients with severe tric

关 键 词：经导管三尖瓣置换术 左心瓣膜术 三尖瓣再次手术 三尖瓣反流 右心衰竭 

分 类 号：R654.2[医药卫生—外科学]